Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32688657 | 0.82 | KDM4E (0.41) | SMN1; SMN2KDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL14257281 | 0.81 | KDM4E (0.59) | SMN1; SMN2KDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL22263574 | 0.81 | ALOX5 (0.63) | LMNAPPARGPPARDPPARA | |
| SCHEMBL559690 | 0.80 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1LMNAPPARGPPARA | |
| SCHEMBL10050755 | 0.78 | CA2 (0.48) | LMNAPPARA | |
| SCHEMBL558881 | 0.78 | KMT2A (0.47) | SMN1; SMN2ALDH1A1LMNAPPARGPPARD | |
| SCHEMBL8347541 | 0.78 | KDM4E (0.68) | SMN1; SMN2KDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL1285778 | 0.78 | PLA2G4B (0.77) | SMN1; SMN2KDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL31061025 | 0.78 | ALOX5 (0.63) | SMN1; SMN2KDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL7484161 | 0.78 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM4ECYP1A2CYP2D6PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130243741-A1 | RENILLA/GAUSSIA TRANSFECTED CELLS AS A LIGHT SOURCE FOR IN-SITU PHOTODYNAMIC THERAPY OF CANCER | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2012040105-A2 | RENILLA/GAUSSIA TRANSFECTED CELLS AS A LIGHT SOURCE FOR IN-SITU PHOTODYNAMIC THERAPY OF CANCER | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130243741-A1 | RENILLA/GAUSSIA TRANSFECTED CELLS AS A LIGHT SOURCE FOR IN-SITU PHOTODYNAMIC THERAPY OF CANCER | PPOX, TFRC, GLB1 | SMN1; SMN2 3920/4885KDM4E 4255/4885CYP1A2 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.